The braking signal again, this time formulated to release over weeks: in this field, delivery is as much of the invention as the sequence.
Identity
- Class
- Somatostatin analog (cyclic octapeptide)
- Source
- Synthetic analog of somatostatin
- Receptor
- Somatostatin receptors (SSTR2 and SSTR5 preferential)
Key properties
Evidence floorClinicalREF1CLIN1Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.
Mechanism
Lanreotide is a somatostatin analog formulated as a long-acting depot (autogel) that releases over weeks, suppressing growth hormone and neuroendocrine secretion much like octreotide. Its prolonged depot kinetics are the practical contrast with the native peptide's minutes-long half-life.
Reference notes
- Delivered as an extended-release depot acting over weeks.
- Shares octreotide's SSTR2/5-preferential profile.
- Used in acromegaly and neuroendocrine tumors.
Regulatory status
United States · reviewed September 2026- Basis
- Somatuline Depot approved for acromegaly and gastroenteropancreatic neuroendocrine tumours.
Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the review date above is the last time the table was checked. Other jurisdictions are noted only where they differ materially.
Common questions
- What is Lanreotide?
- A depot somatostatin analog, similar in action to octreotide. Structurally it is Somatostatin analog (cyclic octapeptide).
- How does Lanreotide work?
- Lanreotide is a somatostatin analog formulated as a long-acting depot (autogel) that releases over weeks, suppressing growth hormone and neuroendocrine secretion much like octreotide. Its prolonged depot kinetics are the practical contrast with the native peptide's minutes-long half-life.
- How strong is the evidence for Lanreotide?
- PeptideHormone grades Lanreotide at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
- What is the half-life of Lanreotide?
- The reported circulating half-life of Lanreotide is depot-dominant (autogel acts over weeks).
- Is Lanreotide FDA-approved?
- Yes — as of September 2026, Lanreotide is an approved prescription medicine in the United States. Somatuline Depot approved for acromegaly and gastroenteropancreatic neuroendocrine tumours. Status is US-centric and can change; check the FDA record for the current position.
- Is Lanreotide the same as Somatuline?
- Somatuline is a brand name of Lanreotide — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.
In the literature
Live registry counts · retrieved- Ph 14
- Ph 230
- Ph 335
- Ph 413
Searched as Lanreotide, Somatuline. Counts are search hits from the primary registries, not a curated set and not a grade – a measure of how much work exists on Lanreotide, not how it turned out.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Acromegaly · Nature reviews. Disease primers, 2019 · PMID 30899019
- 2.Somatostatin Analogs in Clinical Practice: a Review · International journal of molecular sciences, 2020 · PMID 32121432
External references
Lanreotide in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.